GeneDx Announces Partnership with Komodo Health to Expand Access to World’s Largest Rare Disease Dataset
23 April 2024 - 2:30PM
GeneDx (Nasdaq: WGS), a leader in delivering improved health
outcomes through genomic insights, today announced a strategic
partnership with Komodo Health, a premier healthcare technology
company for the pharmaceutical industry. The new partnership will
increase access to GeneDx's extensive de-identified rare disease
data set, now available through Komodo Health’s MapEnhance
offering, including data from more than 500,000 exomes, enabling
biopharma companies to access genetic insights that can help inform
drug pipelines and accelerate clinical trial enrollment.
“The partnership between GeneDx and Komodo Health represents a
milestone in advancing the understanding of rare disease and its
associated drug development”, said Melanie Duquette, Chief Growth
Officer, GeneDx. "We continue to see increased investment in rare
disease drug discovery and want to help accelerate access to these
life changing treatments by making our data more easily accessible
to the companies on the forefront of these discoveries.”
GeneDx's rare disease data set is recognized for its depth and
accuracy, making it a valuable resource for biopharmaceutical
companies seeking to identify novel therapeutic targets and
optimize clinical trial design. As a MapEnhance specialty partner,
GeneDx’s rich repository of de-identified genetic data will be
accessible through Komodo’s end-to-end platform, to help companies
unlock deeper insights into genetically based disease and
accelerate new breakthroughs and treatments for patients.
"Combining the power of GeneDx’s genetic intelligence with
Komodo’s comprehensive and longitudinal view into patient journeys
is going to be a massive accelerant for companies looking to
advance precision medicine and help to pave the way for more
personalized treatments for patients,” said Brad Kelley, General
Manager of MapEnhance, Komodo Health. “We are thrilled to welcome
GeneDx to the MapEnhance family and help our customers more quickly
unravel the intricate genetic underpinnings of diseases."
GeneDx is continuing to showcase its value to biopharma
companies through its participation in the World Orphan Drug
Congress meeting in Boston, April 23-25th. At the meeting, GeneDx
will present a panel “Enabling precision medicine as the standard
of care,” looking at different perspectives of the lab, biopharma
and a parent perspective, on how genomic information can advance
precision medicine. Additional panel details:
Enabling precision medicine as the standard of
care
Thursday, April 25:1:00-1:40pm
Hall C, Theater 1: Diagnosis track
Speakers:
- Amanda Singleton, MPH, ScM, CGC,
Biopharma Partnerships, GeneDx
- Ben Willis, Director of Business
Excellence, Egetis Therapeutics US
- Effie Parks, Podcast Host, Director
of Partnerships, Once Upon a Gene – CTNNB1
GeneDx offers customized solutions for biopharma partners across
all stages of the drug development cycle – from early research
& development to clinical trial recruitment and more.
- Find: Leverage GeneDx’s unmatched
dataset to find clinicians and patients
- Explore: Use clinicogenomic insights
to inform the drug discovery process and cohort builders to inform
market insights
- Partner: Joint
programs aimed at increasing access, accelerating diagnosis, and
finding patients
To learn more about opportunities to partner with GeneDx, please
visit our website or stop by the GeneDx booth, #613 at the World
Orphan Drug Congress
About GeneDxAt GeneDx (Nasdaq: WGS), we believe
that everyone deserves personalized, targeted medical care—and that
it all begins with a genetic diagnosis. Fueled by one of the
world’s largest rare disease data sets, our industry-leading exome
and genome tests translate complex genomic data into clinical
answers that unlock personalized health plans, accelerate drug
discovery, and improve health system efficiencies. It all starts
with a single test. For more information, please visit
www.genedx.com and connect with us on LinkedIn, Facebook, X, and
Instagram.
GeneDx Investor Relations Contact: Investors@GeneDx.com
GeneDx Media Contact: Press@GeneDx.com
About Komodo Health
Komodo Health is a technology platform company creating the new
standard for real-world data and analytics by pairing the
industry’s most complete view of patient encounters with enterprise
software and machine learning that connects the dots between
individual patient journeys and large-scale health outcomes. Across
Life Sciences, payers, providers, and developers, Komodo helps its
customers unearth patient-centric insights at scale — marrying
clinical data with advanced algorithms and AI-powered software
solutions to inform decision-making, close gaps in care, address
disease burden, and help enterprises create a more cost-effective,
value-driven healthcare system. For more information, visit
Komodohealth.com.
Media Contact: media@komodohealth.com
GeneDx (NASDAQ:WGS)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
GeneDx (NASDAQ:WGS)
Historical Stock Chart
Von Mai 2023 bis Mai 2024